Main navigation
Search Results
-
-
Press release - 02/02/2024 University of Stuttgart successful with cluster draft proposals
The German Research Foundation (DFG) has announced the first pivotal decisions for the "Clusters of Excellence" funding line as part of the Excellence Strategy of the German federal and state governments. The University of Stuttgart has been given the green light for two new cluster initiatives.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/universitaet-stuttgart-mit-clusterskizzen-erfolgreich -
Press release - 12/02/2024 AI-supported image analysis: metrics determine quality
How well do the algorithms used in the AI-supported analysis of medical images perform their tasks? This depends to a large extent on the metrics used to evaluate their performance. An international consortium led by scientists from the German Cancer Research Center and the National Center for Tumor Diseases has compiled the knowledge available worldwide on the specific strengths, weaknesses and limitations of the various validation metrics.
https://www.gesundheitsindustrie-bw.de/en/article/news/ai-supported-image-analysis-metrics-determine-quality -
Press release - 06/02/2024 New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration bet- ween both institutions and researchers at the German Cancer Research Center (DKFZ), the Heidelberg Uni- versity, and the Helmholtz Institute for Translational Oncology (HI-TRON).
https://www.gesundheitsindustrie-bw.de/en/article/press-release/neue-t-finder-plattform-liefert-tiefe-einblicke-t-zell-antwort-auf-neuartigen-krebsimpfstoff -
Press release - 10/01/2024 MedTech Company KARL STORZ Acquires British AI Specialist Innersight Labs
The family-owned MedTech company KARL STORZ announces the acquisition of the innovative software manufacturer Innersight Labs Ltd. (ISL) headquartered in London. In addition to state-of-the-art endoscopes, high-end medical devices, and integrated solutions for the operating room, KARL STORZ is also continuing to expand in innovative software solutions.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/medtech-company-karl-storz-acquires-british-ai-specialist-innersight-labs -
Press release - 02/02/2024 Epigenetic status determines metastasis
Scientists from the German Cancer Research Center (DKFZ) and Medical Faculty Mannheim of the Heidelberg University investigated in mice how spreading tumor cells behave at the site of metastasis: Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetischer-status-entscheidet-ueber-metastasierung -
Press release - 31/01/2024 Precursor of Cholesterol Protects Cancer Cells From Cell Death and Makes them Aggressive
A precursor of cholesterol can protect cancer cells from a form of cell death known as ferroptosis. Scientists of the University of Würzburg, the German Cancer Research Center (DKFZ), and the Stem Cell Institute HI-STEM* published this finding in the journal Nature. The results opens up exciting prospects for further improving the treatment of cancer and other diseases associated with oxidative stress and ferroptosis.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/cholesterin-vorstufe-schuetzt-krebszellen-vor-zelltod-und-macht-sie-aggressiver -
Press release - 18/01/2024 Indicator for liver health status identified
A high-fat, high-sugar diet damages the liver in the long term. Scientists at the German Cancer Research Center (DKFZ) have now identified a characteristic change in the molecular signaling pathways of liver cells in mice that were exposed to such a diet for weeks. It fuels the division activity of hepatocytes and correlates with the risk of patients suffering liver failure after liver surgery.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/indicator-liver-health-status-identified -
Press release - 07/02/2024 The unexpected long-term consequences of female fertility
The constant remodeling of the organs of the female reproductive tract during the reproductive cycle leads to fibrosis and chronic inflammation over the years. Scientists from the German Cancer Research Center (DKFZ) have now uncovered these unexpected long-term consequences of female reproductive function in mice. The results have been published in the scientific journal CELL.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/die-unerwartete-auswirkung-der-weiblichen-fortpflanzungsfaehigkeit -
Event - 2nd Biointelligence Congress in Stuttgart
Stuttgart (Germany), Kongress/Symposiumhttps://www.gesundheitsindustrie-bw.de/en/event/2nd-biointelligence-congress-stuttgart -
Press release - 22/02/2024 A new approach to recording cellular activities
In living cells, a vast number of transient events occur simultaneously. The recording of these activities is a prerequisite for a molecular understanding of life. Scientists at the MPI for Medical Research in Heidelberg and their collaboration partners have created a novel technology that allows cellular events to be recorded through chemical labeling with fluorescent dyes for later analysis, opening up new ways to study cellular physiology.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-recording-cellular-activities -
Press release - 04/03/2024 Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranches Cumulative royalties sold are capped at a maximum value
https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-announces-royalty-financing-agreement-healthcare-royalty-usd-115-million -
Stem cell research - 14/03/2024 Using organoids to gain a better clinical understanding of pancreatic cancer
Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.
https://www.gesundheitsindustrie-bw.de/en/article/news/using-organoids-gain-better-clinical-understanding-pancreatic-cancer -
Press release - 15/02/2024 Modelling the spread of diseases
Computer scientists from the Cluster of Excellence Collective Behaviour developed a model, that explains how collective scenarios such as diseases may proceed.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/modelling-spread-diseases -
Press release - 01/03/2024 Using Data to Improve Understanding of Relationships between Proteins and Diseases
Working with a new Emmy Noether Group, Dr. Pascal Schlosser is investigating how machine learning can aid in understanding the complex relationships between genes, proteins, and diseases.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-data-improve-understanding-relationships-between-proteins-and-diseases -
Epifadin from the nasal microbiome - 28/03/2024 From the nose: novel antibiotic substance discovered
Antibiotics are becoming an increasingly blunt weapon against infectious diseases. The number of (multi-)resistant germs has been rising rapidly for years and even reserve antibiotics no longer work. Researchers at the University of Tübingen have now isolated a completely new antibiotic substance called epifadin from the microbiome of the human nose. It is effective against many different bacteria - including the dangerous hospital MRSA.
https://www.gesundheitsindustrie-bw.de/en/article/news/nose-novel-antibiotic-substance-discovered -
App for tuberculosis diagnosis - 15/05/2024 "Find-TB" aims to improve access to tuberculosis diagnostics
Globally, the majority of children with tuberculosis remain undiagnosed and therefore untreated because their symptoms are categorised incorrectly. Researchers at Heidelberg University Hospital want to develop an app that analyses medical information, risk factors and local surveillance data to calculate individual risk of infection and test those who might be affected with TB as early as possible.
https://www.gesundheitsindustrie-bw.de/en/article/news/find-tb-aims-improve-access-tuberculosis-diagnostics -
Event - - GCSB 2024 German Conference on Synthetic Biology 2024
Regensburg, Kongress/Symposiumhttps://www.gesundheitsindustrie-bw.de/en/event/gcsb-2024-german-conference-synthetic-biology-2024 -
Event - - Curious2024 – Future Insight™ Conference
Mainz, Kongress/Symposiumhttps://www.gesundheitsindustrie-bw.de/en/event/curious-2024-future-insight-conference -
Press release - 22/03/2024 Decoding the shared genetic toolkit for male sex determination
Researchers from the Max Planck Institute for Biology Tübingen broke new ground by demonstrating that an HMG-box gene in brown algae is crucial for determining male sex. This breakthrough significantly expands our understanding of sex-determination mechanisms in eukaryotic organisms. Until now, master sex-determination genes had been identified in only a select number of animals and plants.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/decoding-shared-genetic-toolkit-male-sex-determination -
Press release - 14/03/2024 Next milestone in the treatment of liver tumors and acute and chronic liver diseases
The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…
https://www.gesundheitsindustrie-bw.de/en/article/press-release/next-milestone-treatment-liver-tumors-and-acute-and-chronic-liver-diseases -
Press release - 05/03/2024 New Center for Synthetic Genomics
Applying and developing new technologies for DNA synthesis to pave the way for producing entire artificial genomes – that is the goal of a new interdisciplinary center, 'Center for Synthetic Genomics', that is being established at Heidelberg University, Karlsruhe Institute of Technology (KIT), and Johannes Gutenberg University Mainz (JGU).
https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-center-synthetic-genomics -
Press release - 13/03/2024 Diabetes: New technology opens up improved opportunities for research
More than seven million people in Germany suffer from diabetes. At the same time, research into drugs to treat this widespread disease is still difficult. Scientists led by Prof. Dr. Peter Loskill from the NMI Natural and Medical Sciences Institute and the Faculty of Medicine of the Eberhard Karls University of Tübingen have now developed a technique that significantly improves the view at the molecular and cell biological level in the pancreas.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/diabetes-new-technology-opens-improved-opportunities-research -
Press release - 04/03/2024 First Step Toward Early Diagnosis of Metastasis
Team involving the University of Freiburg has developed a new analytical method for the basement membrane in human lungs.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-step-toward-early-diagnosis-metastasis -
Press release - 14/03/2024 Machine learning classifier accelerates the development of cellular immunotherapies
Making a personalised T cell therapy for cancer patients currently takes at least six months; scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can be replaced with a machine learning classifier that halves this time.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/machine-learning-classifier-accelerates-development-cellular-immunotherapies -
Press release - 13/03/2024 Protection from an unexpected source
Contrary to common belief, not all viruses are harmful to their hosts. Sometimes viruses can even protect their hosts from infection by other viruses. Scientists at the Max-Planck-Institute for Medical Research in Heidelberg and their collaborators have now demonstrated that this is the case for so-called endogenous virophages: small DNA viruses that are mostly found inserted into the genomes of single-cell eukaryotes.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/protection-unexpected-source -
Press release - 22/03/2024 New Emmy Noether junior research group for biological data science
An Emmy Noether junior research group at Heidelberg University is investigating how to gain new insights into fundamental biological mechanisms from large-scale molecular data sets. Led by Junior Professor Dr Britta Velten, it has started work at the Centre for Organismal Studies and the Interdisciplinary Center for Scientific Computing.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-emmy-noether-junior-research-group-biological-data-science -
Press release - 14/03/2024 Planned NMI spin-off: immuneAdvice successful in start-up competition
Does our therapeutic approach work against cancer? The answer to this question can make the difference between life and death - and is still difficult to answer. A team from the NMI Natural and Medical Sciences Institute at the University of Tübingen and the Werner Siemens Imaging Center Tübingen has developed a technique for observing immune cells.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/geplante-nmi-ausgruendung-immuneadvice-bei-startup-wettbewerb-erfolgreich -
Press release - 10/04/2024 Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform
With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/growth-through-medical-technology-bosch-and-randox-invest-heavily-vivalytic-analysis-platform -
Press release - 18/04/2024 Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform
The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/additional-partnership-medical-technology-bosch-and-r-biopharm-strengthen-vivalytic-analysis-platform -
Press release - 02/04/2024 Precise localization of miniature robots and surgical instruments inside the body
In the medicine of the future, tiny robots will navigate independently through tissue and medical instruments will indicate their position inside the body during surgery. Both require doctors to be able to localize and control the devices precisely and in real time. Scientists from the German Cancer Research Center (DKFZ) have now described a signaling method based on an oscillating magnet that can significantly improve such medical applications.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/precise-localization-miniature-robots-and-surgical-instruments-inside-body -
Press release - 10/04/2024 Cyber Valley grants 500K to CELL’n’ROLL via 2023 Innovation Fellowship Program
Pioneering cutting-edge diagnostic systems for the detection of complex diseases: Cyber Valley is pleased to announce it has awarded funding of 500K EUR to the CELL’n’ROLL team through the 2023 Cyber Valley Innovation Fellowship program, funded by the Carl-Zeiss-Stiftung.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-grants-500k-cellnroll-2023-innovation-fellowship-program -
Press release - 18/04/2024 Collagen: Researchers at the NMI decipher how it works in medical treatment
Collagen has been used in ophthalmology since the 1990s, particularly in the treatment of corneal defects. However, why and how this technique works was only known in theory. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen led by Lu Fan have found the necessary evidence and can now reliably explain how this technique works.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/collagen-researchers-nmi-decipher-how-it-works-medical-treatment -
Press release - 27/03/2024 Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).
https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-granted-orphan-drug-designation-fda-its-proprietary-atac-candidate-hdp-101 -
Innovation in emergency medicine - 23/05/2024 CARL pushes back the boundaries of resuscitation therapy
Few people survive a cardiac arrest; blood stops flowing to the brain and other vital organs and the resulting lack of oxygen causes extensive damage to the body. In response to this, researchers at the University Medical Centre Freiburg and Resuscitec GmbH have developed CARL, an innovative resuscitation system, which – in addition to the oxygen level – adjusts numerous blood parameters to individual patient requirements. This greatly improves…
https://www.gesundheitsindustrie-bw.de/en/article/news/carl-pushes-back-boundaries-resuscitation-therapy -
Event - - Diagnostics-4-Future Conference 2024
Konstanz, Germany, Conferencehttps://www.gesundheitsindustrie-bw.de/en/event/diagnostics-4-future-conference-2024 -
Event - - The MedTech Forum 2024
Vienna, Austria, Conferencehttps://www.gesundheitsindustrie-bw.de/en/event/medtech-forum-2024 -
Press release - 03/05/2024 Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies
Activated T cells that carry a certain marker protein on their surface are controlled by natural killer cells. In this way, the body presumably curbs destructive immune reactions. Researchers now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-mechanism-t-cell-control-can-interfere-cancer-immunotherapies -
Press release - 07/05/2024 Intermittent fasting protects against liver inflammation and liver cancer / Drug partially mimics fasting effects
Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/intermittent-fasting-protects-against-liver-inflammation-and-liver-cancer-drug-partially-mimics-fasting-effects -
Press release - 15/05/2024 Tumour tissue on a chip: new possibilities for cell therapies and personalized medicine
How do tumors react to a certain therapeutic approach? Knowing this before the start of a therapy would be of enormous value for people suffering from cancer as well as for the doctors treating them. Researchers have now made this very observation possible for the CAR-T cell therapy. This allows us to individually investigate how exactly these tumor cells react to the planned therapy.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/tumour-tissue-chip-new-possibilities-cell-therapies-and-personalized-medicine -
Press release - 16/05/2024 Colorectal cancer: tracking down subtypes
Colorectal cancer differs from patient to patient. That is why scientists are looking for characteristic tumors markers that allow to make predictions about the likely response to certain therapies and the individual prognosis. The aim is to identify colorectal cancer subtypes so that these can then be treated in a customized manner.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-tracking-down-subtypes -
Press release - 11/04/2024 How the body switches out of “fight” mode Study in Nature unlocks how cortisone inhibits inflammation
Cortisone and other related glucocorticoids are extremely effective at curbing excessive immune reactions. But previously, astonishingly little was known about how they exactly do that. A team of researchers from Charité – Universitätsmedizin Berlin, Uniklinikum Erlangen and Ulm University have now explored the molecular mechanism of action in greater detail.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-der-kampfmodus-im-koerper-beendet-wird-studie-nature-entschluesselt-wie-kortison-entzuendungen-daempft -
Press release - 24/05/2024 Research Training Group on Cancer Surgery: German Research Foundation approves second funding period
Since 2019, the Research Training Group (RTG) "Intraoperative Multisensoric Tissue Differentiation in Oncology," a collaboration between the University of Stuttgart and the University of Tübingen, has been advancing research in medical technology. With the help of new sensor methods, the researchers want to help make surgical procedures on cancer patients safer and more effective.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-training-group-cancer-surgery-german-research-foundation-approves-second-funding-period -
Press release - 17/04/2024 Cell Biology: Molecular Code Stimulates Pioneer Cells to Build Blood Vessels in the Body
Cardiovascular diseases, including stroke and myocardial infarction, are the world's leading causes of mortality, accounting for over 18 million deaths a year. A team of KIT researchers has now identified a new cell type in blood vessels responsible for vascular growth. This discovery may allow for novel therapeutic strategies to treat ischemic cardiovascular diseases, i.e. diseases that are caused by reduced or absent blood flow.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/zellbiologie-molekularer-code-regt-pionierzellen-zum-aufbau-von-blutgefaessen-im-koerper -
Press release - 25/04/2024 Diamond dust shines bright in Magnetic Resonance Imaging
An unexpected discovery surprised a scientist at the Max Planck Institute for Intelligent Systems in Stuttgart: nanometer-sized diamond particles, which were intended for a completely different purpose, shone brightly in a magnetic resonance imaging experiment – much brighter than the actual contrast agent, the heavy metal gadolinium. Could diamond dust one day become a novel contrast agent used for MRI?
https://www.gesundheitsindustrie-bw.de/en/article/press-release/diamond-dust-shines-bright-magnetic-resonance-imaging -
Press release - 06/05/2024 Research under high pressure
Why 3,000 bars are needed to take a comprehensive look at a protein: Konstanz researchers Frederic Berner and Michael Kovermann present a new high-pressure spectroscopy method to unravel the properties of proteins' native structures.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-under-high-pressure -
Press release - 13/05/2024 Detecting respiratory infections: simply blow for diagnosis
Professor Claudia Denkinger from Heidelberg University's Faculty of Medicine is leading the international collaborative project "BreathForDiagnosis". Researchers from Germany, Italy, South Africa and Romania are working with an industrial partner from Switzerland to develop user-friendly breath tests for the rapid diagnosis of respiratory infections such as tuberculosis.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/detecting-respiratory-infections-simply-blow-diagnosis -
Press release - 19/04/2024 Electrified bacteria
PhD student at Furtwangen University develops method for faster determination of antibiotic resistance. The increase in antibiotic-resistant pathogens and the associated treatment, which is a major problem in public healthcare facilities, is the subject of a research project at Furtwangen University.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/bakterien-unter-strom -
Press release - 24/04/2024 CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat. Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-start-combined-phase-12-study-avian-influenza-h5n1-development-collaboration-gsk -
Press release - 31/05/2024 Heidelberg University successful with six bids for collaborative research
In the current approval round of the German Research Foundation (DFG) Heidelberg University has been successful with six applications for grants to fund major, internationally visible research consortia. The six research consortia − three of them will reach the maximum funding length of twelve years after their extension − are to receive financial resources totalling nearly 87 million euros over a period of four years.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-university-successful-six-bids-collaborative-research